A Multinational, Multicenter, Open-Label, Single-Assignment Extension of the MS-LAQ-302 (BRAVO) Study, to Evaluate the Long-term Safety, Tolerability and Effect Disease Course of Daily Oral Laquinimod .6mg in Subjects with Relapsing Multiple Sclerosis, Teva Neuroscience